Sort   by:  
 Page size 
TranscriptomicsGene expression associated with lentiviral expression of PRAME in normal hematopoietic progenitors.
To identify gene expression that distinguishes hematopoietic cells that express PRAME from those that do not, normal CD34+ cells with forced PRAME expression were compared to cells without PRAME expression in culture over time (days 4, 7, 14) using Affymetrix HU-133A microarrays Normal CD34+ progen...
ORGANISM(S): Homo sapiens 
2009-10-31 | E-GEOD-17100 | biostudies-arrayexpress
TranscriptomicsThe tumor antigen PRAME is a substrate recognition subunit of a Cul2-based ubiquitin ligase and is associated with active NFY promoters
The human tumor antigen PRAME (Preferentially expressed antigen of melanoma) is frequently overexpressed in tumors. High PRAME levels correlate with poor clinical outcome of several cancers, but the mechanisms by which PRAME could be involved in tumorigenesis remain largely elusive. We applied prote...
ORGANISM(S): Homo sapiens 
2011-07-29 | E-GEOD-26439 | biostudies-arrayexpress
TranscriptomicsPRAME induced inhibition of retinoic acid receptor signaling-mediated differentiation - a possible target for ATRA response in AML without t(15;17)
Purpose: In acute myeloid leukemia (AML) without retinoic acid receptor (RAR) rearrangement the effect of all-trans retinoic acid (ATRA) is still poorly understood despite an association of NPM1 mutation and ATRA response. Recently, PRAME (preferentially expressed antigen in melanoma) has been shown...
ORGANISM(S): Homo sapiens 
2013-03-10 | E-GEOD-43258 | biostudies-arrayexpress
ProteomicsPRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer
Recurrent disease emerges in the majority of patients with ovarian cancer (OVCA). Adoptive T-cell therapies with T-cell receptors (TCRs) targeting tumor-associated antigens (TAAs) are considered promising solutions for less-immunogenic ‘cold’ ovarian tumors. In order to treat a broader patient popul...
ORGANISM(S): Homo sapiens (Human) 
2023-03-10 | PXD040651 | Pride
Ovarian cancer  prame  ctcfl  cldn6  tcr gene transfer  t-cell therapy  immunotherapy  peptide  allogeneic hla 
TranscriptomicsGene expression profile of Hodgkin’s lymphoma cells after knock-down of PRAME
By using high-density DNA microarrays, we analyzed the gene-expression profile of Hodgkin's lymphoma cell line L-428 after knock-down of the tumor antigen PRAME (preferentially expressed antigen in melanoma) Kewitz and Staege, submitted RNA was extracted from established Hodgkin's lymphoma cell line...
ORGANISM(S): Homo sapiens 
2012-12-21 | E-GEOD-40988 | biostudies-arrayexpress
TranscriptomicsGene expression profiling of PRAME-positive and PRAME-negative osteosarcoma samples
Preferentially Expressed Antigen in Melanoma (PRAME) is frequently overexpressed in a wide variety of cancers and it has been proposed as prognostic marker for clinical outcome. It belongs to a class of non-mutated genes whose expression seems to be mostly restricted to tumor cells. Osteosarcoma is ...
ORGANISM(S): Homo sapiens 
2010-05-18 | E-GEOD-8079 | biostudies-arrayexpress
GenomicsPRAME-mediated retinoid resistance in keratinocyte carcinomas is overcome by EZH2 inhibition
PRAME-mediated retinoid resistance in keratinocyte carcinomas is overcome by EZH2 inhibition
PRJNA1129865 | ENA
GenomicsPRAME induces genomic instability in uveal melanoma [RNA-seq]
PRAME induces genomic instability in uveal melanoma [RNA-seq]
PRJNA964758 | ENA
GenomicsShared PRAME epitopes are T-Cell Targets in NUT Carcinoma
Shared PRAME epitopes are T-Cell Targets in NUT Carcinoma
PRJNA1494203 | ENA
GenomicsTranscriptomic profiling of PRAME knockdown in SKOV3 and ES2 ovarian cancer cells
Transcriptomic profiling of PRAME knockdown in SKOV3 and ES2 ovarian cancer cells
PRJNA1530341 | ENA
Sort   by:  
 Page size